Genetic alterations of prostate cancer: in localized and metastatic prostate cancer
Authors:
Open Access
- 14 July 2025
- journal article
- research article
- Published by Springer Nature in BMC Urology
- Vol. 25 (1) , 1-10
Abstract
Purpose: The purpose of this study was to identify genetic mutations in patients with localized and metastatic prostate cancer, exploring the relationship between these mutations and clinical outcomes. Materials and methods: We conducted next-generation sequencing on tissue samples from 106 prostate cancer patients at Seoul St. Mary’s Hospital, analyzing prostate-specific antigen (PSA) levels, tumor, node, metastasis (TNM) staging, Gleason score (GS), and clinical course, including treatment modalities and biochemical recurrence (BCR). Results: The study included 65 patients with localized and 41 with metastatic prostate cancer. Significant differences were noted in PSA levels, T stage, GS, and treatment modalities. We observed prevalent single-nucleotide variations (SNVs), copy number variations (CNVs), and structural variations including gene fusions like TMPRSS2-ERG. Key predictors of metastatic prostate cancer identified were T stage, GS, PIK3CA, LRP6, LRRK2, and APOBEC3B deletion. BRCA2, BCL6, and CHEK2 were significant predictors for BCR. Conclusion: Our findings suggest that specific genetic mutations, including PIK3CA, LRP6, LRRK2, and BRCA2, are linked to prostate cancer metastasis and BCR. These results highlight the potential of genetic analysis in forecasting the prognosis of prostate cancer patients and guiding therapeutic decisions.Keywords
This publication has 31 references indexed in Scilit:
- The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory RevisitedEuropean Urology, 2021
- Impact of positive surgical margin status in predicting early biochemical recurrence after robot-assisted radical prostatectomyInternational Journal of Clinical Oncology, 2021
- Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate CancerEuropean Urology, 2020
- Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in PolandInternational Journal of Cancer, 2020
- Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort StudyEuropean Urology, 2020
- Integrative Clinical Genomics of Advanced Prostate CancerCell, 2015
- Higher Frequency of Certain Cancers inLRRK2G2019S Mutation Carriers With Parkinson DiseaseJAMA Neurology, 2015
- Salinomycin Suppresses LRP6 Expression and Inhibits Both Wnt/β‐catenin and mTORC1 Signaling in Breast and Prostate Cancer CellsJournal of Cellular Biochemistry, 2014
- Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease HeterogeneityEuropean Urology, 2013
- The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen DeprivationThe Prostate, 2011